(NASDAQ: PCRX) Pacira Biosciences's forecast annual revenue growth rate of 6.3% is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 6.44%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 7.66%.
Pacira Biosciences's revenue in 2023 is $665,689,000.On average, 6 Wall Street analysts forecast PCRX's revenue for 2023 to be $31,171,540,999, with the lowest PCRX revenue forecast at $30,925,653,356, and the highest PCRX revenue forecast at $31,345,450,200. On average, 6 Wall Street analysts forecast PCRX's revenue for 2024 to be $33,708,711,394, with the lowest PCRX revenue forecast at $32,824,026,695, and the highest PCRX revenue forecast at $34,925,332,801.
In 2025, PCRX is forecast to generate $37,309,816,026 in revenue, with the lowest revenue forecast at $36,349,577,183 and the highest revenue forecast at $38,896,220,870.